ArriVent Biopharma, dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the completion of a $155 million oversubscribed Series B financing. The proceeds will be used to support pivotal Phase 3 and additional studies with the Company's lead product candidate furmonertinib-a highly brain penetrant, mutant-specific EGFR kinase inhibitor-as well as the continued expansion of its pipeline.

The financing was led by Sofinnova Investments and General Catalyst, with participation from additional new investors including Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, and Infinitum Asset Management.

All existing investors-which include Lilly Asia Ventures, OrbiMed, Octagon Capital Advisors, Sirona Capital, and Boyu/Zoo Capital-also participated in the round. Commensurate with this financing, Jim Healy, Sofinnova Investments, and Carl Gordon, OrbiMed Advisors, will be joining ArriVent's board of directors.